Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques (Q57697548)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques	article

Statements

scholarly article

0 references

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques (English)

0 references

1 reference

based on heuristic

inferred from title

post-exposure prophylaxis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

David C. Montefiori

9

object named as

David C. Montefiori

0 references

Flavia Ferrantelli

object named as

Flavia Ferrantelli

1

0 references

Regina Hofmann-Lehmann

object named as

Regina Hofmann-Lehmann

8

0 references

author name string

Kathleen A. Buckley

2

0 references

Robert A. Rasmussen

3

0 references

Alistair Chalmers

4

0 references

Tao Wang

5

0 references

Pei-Lin Li

6

0 references

Alison L. Williams

7

0 references

Lisa A. Cavacini

10

0 references

Hermann Katinger

11

0 references

Gabriela Stiegler

12

0 references

Daniel C. Anderson

13

0 references

Harold M. McClure

14

0 references

Ruth M. Ruprecht

15

0 references

language of work or name

0 references

publication date

February 2007

0 references

0 references

358

0 references

1

0 references

69-78

0 references

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Mucosal immunity: integration between mother and the breast-fed infant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antibodies: can they protect against HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.056

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.07.056

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57697548&oldid=1648103655"